bluebird bio (Nasdaq:BLUE) - Stock Price, News & Analysis

BLUE Stock Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.

About the company

BLUE fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 40.56% per year

Earnings have grown 18.9% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

bluebird bio, Inc. Competitors

Rigel Pharmaceuticals

NasdaqGS:RIGL

US$199.9m

Puma Biotechnology

NasdaqGS:PBYI

US$245.9m

Vanda Pharmaceuticals

NasdaqGM:VNDA

US$233.0m

2seventy bio

NasdaqGS:TSVT

US$249.4m

Price History & Performance

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share Price	US$0.96
52 Week High	US$5.53
52 Week Low	US$0.88
Beta	0.80
1 Month Change	-33.10%
3 Month Change	-30.70%
1 Year Change	-72.00%
3 Year Change	-96.57%
5 Year Change	-99.29%
Change since IPO	-96.42%

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Recent updates

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

Feb 07

bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success

Dec 12

bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

Nov 08

bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea

Nov 03

Shareholder Returns

	BLUE	US Biotechs	US Market
7D	-19.1%	-4.2%	-3.7%
1Y	-72.0%	-2.0%	20.5%

Return vs Industry: BLUE underperformed the US Biotechs industry which returned -1.7% over the past year.

Return vs Market: BLUE underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is BLUE's price volatile compared to industry and market?
BLUE volatility
BLUE Average Weekly Movement	15.8%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.0%

Stable Share Price: BLUE's share price has been volatile over the past 3 months.

Volatility Over Time: BLUE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1992	323	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.

bluebird bio, Inc. Fundamentals Summary

How do bluebird bio's earnings and revenue compare to its market cap?
BLUE fundamental statistics
Market cap	US$190.87m
Earnings (TTM)	-US$91.17m
Revenue (TTM)	US$21.73m

8.5x

P/S Ratio

-2.0x

P/E Ratio

Is BLUE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLUE income statement (TTM)
Revenue	US$21.73m
Cost of Revenue	US$255.71m
Gross Profit	-US$233.98m
Other Expenses	-US$142.81m
Earnings	-US$91.17m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.47
Gross Margin	-1,076.97%
Net Profit Margin	-419.62%
Debt/Equity Ratio	0%

How did BLUE perform over the long term?

See historical performance and comparison

BLUE Stock Overview

Rewards

Risk Analysis

bluebird bio, Inc. Competitors

NasdaqGS:RIGL

US$199.9m

NasdaqGS:PBYI

US$245.9m

NasdaqGM:VNDA

US$233.0m

NasdaqGS:TSVT

US$249.4m

Price History & Performance

Recent News & Updates

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Recent updates

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates fall by 13%

Price target decreased by 8.2% to US$6.61

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 31% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

Now 24% undervalued after recent price drop

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Consensus revenue estimates decrease by 26%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Bluebird bio names interim finance chief

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

Bluebird bio jumps 17% on FDA approval of new gene therapy

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

bluebird bio' chief strategy and financial officer to depart

Treasurer recently sold US$78k worth of stock

Consensus forecasts updated

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

President recently sold US$96k worth of stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$8.22

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold US$6.7k worth of stock

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Consensus forecasts updated

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential